Cite
Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908doi: 10.1155/2009/305908.
Fountzilas, G., Kalogera-Fountzila, A., Lambaki, S., Wirtz, R. M., Nikolaou, A., Karayannopoulou, G., Bobos, M., Kotoula, V., Murray, S., Lambropoulos, A., Aravantinos, G., Markou, K., Athanassiou, E., Misailidou, D., Kalogeras, K. T., & Skarlos, D. (2009). MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of oncology, 2009305908. https://doi.org/10.1155/2009/305908
Fountzilas, George, et al. "MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer." Journal of oncology vol. 2009 (2009): 305908. doi: https://doi.org/10.1155/2009/305908
Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908. doi: 10.1155/2009/305908. Epub 2009 Dec 29. PMID: 20066159; PMCID: PMC2801452.
Copy
Download .nbib